Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Prostate Cancer”

191 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 191 results

Not applicableStudy completedNCT01366053
What this trial is testing

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Who this might be right for
Prostate Cancer
CMX Research 125
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Not applicableActive Not RecruitingNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 504
Testing effectiveness (Phase 2)Active Not RecruitingNCT06734130
What this trial is testing

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)Study completedNCT01120236
What this trial is testing

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Who this might be right for
Prostate AdenocarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
National Cancer Institute (NCI) 211
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Testing effectiveness (Phase 2)WithdrawnNCT05705700
What this trial is testing

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Who this might be right for
Prostate Cancer
Masonic Cancer Center, University of Minnesota
Not applicableUnknownNCT05161728
What this trial is testing

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Roderick van den Bergh 150
Testing effectiveness (Phase 2)Study completedNCT01784913
What this trial is testing

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Ultimovacs ASA 22
Not applicableLooking for participantsNCT07146113
What this trial is testing

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who this might be right for
Prostate Cancer
AstraZeneca 400
Large-scale testing (Phase 3)Looking for participantsNCT06177015
What this trial is testing

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Who this might be right for
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University 200
Early research (Phase 1)Active Not RecruitingNCT05079698
What this trial is testing

Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 29
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Early research (Phase 1)Not Yet RecruitingNCT06099990
What this trial is testing

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 660
Testing effectiveness (Phase 2)Active Not RecruitingNCT03860987
What this trial is testing

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Who this might be right for
Castrate Sensitive Prostate Cancer
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04619069
What this trial is testing

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Sunnybrook Health Sciences Centre 60
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Very early researchActive Not RecruitingNCT03511196
What this trial is testing

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Who this might be right for
Prostate CancerStage IV Prostate CancerAdvanced Prostate Cancer+1 more
H. Lee Moffitt Cancer Center and Research Institute 17
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Post-approval studies (Phase 4)Study completedNCT00219219
What this trial is testing

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Who this might be right for
Prostate Cancer
Novartis
Load More Results